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Abstract
Summary Clinicians need tools to identify patients most
likely to benefit from bone mineral density (BMD) testing,
for which cost–effectiveness does not allow generalized
screening. This study supports the utility of osteoporosis
risk assessment tools in selecting men for BMD testing.
Different cutoff values may be appropriate for different
countries and/or ethnic origins.
Introduction Our aim was to evaluate the utility of three
osteoporosis (OP) risk assessment tools in a large group of
Portuguese men aged 50 or more and to determine the best
cutoff value to be used for selecting men for bone densitometry.
Methods We assessed the performance of three simple tools
in 202 randomly selected men: body weight criterion
(BWC), osteoporosis self-assessment tool for Asians
(OSTA), and a modified version of the OSTA equation
(OST). Previously published cutoff values (validated in
postmenopausal women) and three additional cutoff values
were tested. Sensitivity (SE), specificity (SP), predictive
values, and area under the receiver operating characteristic
(AUROC) curve for correctly selecting men with OP
(defined by BMD testing) were determined.
Results Mean age of the cohort was 63.8 years. According to
the World Health Organization diagnostic categories, 16.8%
had osteoporosis. The best performing cutoffs for correctly
selecting men with OP for BMD testing were OST<3 (SE=
75.5%, SP=50.0%, AUROC=0.632), OSTA<3 (SE=73.5%,
SP=58.3%, AUROC=0.659), and BWC<75 kg (SE=73.5%,
SP=61.3%, AUROC=0.674).
Conclusions OP risk assessment tools seem to be useful in
men aged 50 or more. Best cutoff values are different from
those recommended for postmenopausal women. Different
cutoff values may be appropriate for different countries
and/or ethnic origins.
Keywords Densitometry .Mass screening .Men .
Osteoporosis . Portugal . Risk assessment
Introduction
Osteoporosis continues to be an underrecognized problem in
men, and it still goes untreated in the majority of men even in
the presence of fractures. One in five men over the age of
50 years will experience an osteoporosis-related fracture in
their lifetime [1]. Of all osteoporotic fractures, hip fractures
contribute to the greatest morbidity, as well as mortality, both
of which are greater in men than in women [2, 3]. With the
increasing longevity of men, osteoporosis in this gender will
soon become an even greater burden to society and health
care systems worldwide. It has been estimated that by the
year 2040, there will be as many hip fractures worldwide in
men as was seen in women in the year 2000 [4].
Many well-controlled prospective studies with dual-energy
X-ray absorptiometry (DXA), particularly in elderly women,
indicate that the risk of fracture about doubles for each
standard deviation (SD) reduction in bone mineral density
(BMD) [5]. BMD measurements can be useful in several
ways, including contributing to the diagnosis of skeletal
fragility, gauging its severity, and guiding decisions
concerning therapy.
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There is a progressive tendency to recommend the
identification of individuals for treatment based on a
comprehensive fracture risk assessment rather than BMD
status alone. A fracture risk assessment tool (FRAX™)
[6] has recently been developed based on the use of
clinical risk factors with or without BMD. However, the
importance of the World Health Organization (WHO)
categories in the decision making remains high, and
clinicians will still have to face the question about which
individuals to select for DXA measurements. This
question is also implicit when considering (or not) the
incorporation of BMD in the previously mentioned
fracture risk equation.
Screening for osteoporosis with bone density measures
has been recommended for men over 70 years [7, 8] and is
worth further evaluation as a strategy. However, a recent
cost–effectiveness analysis supported generalized screening
only in those over 80 years, as well as in men over the
age of 65 years who have previously experienced a
fracture [9]. DXA is readily available, there are well-
developed reference data for its use, and DXA BMD
levels are strongly related to fracture risk in men [10, 11].
Moreover, pharmacological therapies appear to be effec-
tive in men chosen on the basis of low DXA BMD levels
[12–15]. For all these reasons, DXA must be considered
the first choice for assessing bone strength in men, but
cost and effectiveness does not allow for generalized
screening and advises the use of some selection of the
target population.
Reviews about the clinical applications of bone
densitometry suggest that clinicians need tools to identify
patients most likely to benefit from DXA testing [16, 17].
A simple risk assessment tool may also have value for
increasing the awareness of osteoporosis and for encouraging
more efficient use of BMD measurements, that is, in patients
who have a higher probability of low BMD, especially in
otherwise healthy, asymptomatic patients. Several studies
have examined and confirmed the ability of individual risk
factors to identify postmenopausal women likely to have
osteoporosis and some have proposed simple composite
tools obtained by questionnaire and based on a score [3, 18–
27]. The purpose of these risk assessment indices is not to
diagnose osteoporosis or low BMD but to identify people
who are more likely to have low BMD and should, therefore,
be submitted to DXA. The easier to use in clinical practice
are certainly the osteoporosis self-assessment tool [3, 27] and
the body weight criterion [19]. They have been validated for
women of diverse origins, including Asian and Caucasian [3,
28–32]. The evidence for the utility of these rules in a
clinical setting is scarce and few studies have been
performed in men [33–40]. Their utility is not necessarily
the same in males and females and in different populations,
as the contribution of osteoporotic factors may vary.
Therefore, we aimed to assess the validity and to
establish the best cutoff values for the OSTA, OST, and
BWC criteria in men, using a large group of randomly
selected Portuguese males aged 50 or more.
Materials and methods
Data collection
Data collection took place in Santo António dos Olivais
(SAOL), Coimbra, Portugal, in the years of 1998 and 1999.
The methodology has been previously described [41]. This
county has a mixture of rural and urban population, which
presents epidemiological patterns of age and gender
distribution, income, and consumer habits considered to
be similar to those of the general Portuguese population. It
has about 25,000 inhabitants. Residents were randomly
selected from the 19,000 registered voters following a
computer-generated random number list, stratified to
gender and 5 year age groups. People were invited to
participate by mail explaining the nature and purposes of
the study. There were no exclusion criteria. Nonrespondents
were contacted a second time. We aimed at a total of at least
1,600 participants. A total of 6,000 invitations were sent out
before this number was reached; 1,100 letters bounced back
due to change in address, death, and other reasons.
Altogether, 1,745 accepted to participate.
Participants responded to a comprehensive questionnaire
regarding risk factors for osteoporosis in personal and family
history. Height and weight were recorded. DXA scans of the
spine and proximal femur were performed, using a Hologic
QDR 4500/c bone densitometer. Scans were performed and
analyzed according to the manufacturer’s instructions.
Seventy-three participants were excluded from final analysis
due to incomplete data or unresolved technical difficulties in
the DXA scan. A total of 1,706 participants were studied
(1,233 women and 473 men). For the purposes of this study,
all men aged 50 or more were included (study cohort=202).
Calculating decision algorithm scores
Based on a critical review of the literature, with consideration
of published performance indicators and simplicity, we
selected three simple decision algorithms to test: the
body weight criterion (BWC) [19], the osteoporosis
self-assessment tool for Asians (OSTA) [27], and a
modified version of the OSTA equation (OST) [3, 27].
Their scoring methods, with previously validated selection
cutoff points in postmenopausal women, are presented in
Table 1. All the information needed were available in the




BMD values as assessed by DXA were used as the gold
standard for diagnosing osteoporosis. We used the WHO
thresholds to classify our patients into three diagnostic
categories: normal (T-score≥−1.0 SD), osteopenic (−1.0>
T-score>−2.5 SD), or osteoporotic (T-score≤−2.5 SD). The
young normal reference values used for the calculation of
T-scores were National Health and Nutrition Examination
Survey III reference for the hip [42] and the HOLOGIC
male Caucasian reference database for the spine. In each
case, the lowest BMD T-score at the lumbar spine (L1–L4),
femoral neck, or total hip was considered.
Statistical analysis
Descriptive characteristics of the study population were
tabulated as means and SD, or proportions as applicable.
Differences among groups of patients were calculated by
analysis of variance or chi-square test as applicable.
Pearson’s correlation coefficient was used to assess the
relationship between age and T-score values. Significance
was determined using a two-sided α level of 0.05.
The sensitivity, specificity, positive predictive value,
negative predictive value (NPV), and the area under the
receiver operating characteristic (AUROC) curve of each
decision algorithm for selecting men with osteoporosis by
BMD testing were determined.
Sensitivity was defined as the proportion of men with
osteoporosis (T-score≤−2.5 SD) who tested positive on the
decision algorithm (indication for DXA in the binomial
classification) and specificity was defined as the proportion
of men without osteoporosis who tested normal on the risk
assessment (having index values in the range considered
low risk). Positive predictive value was defined as the
proportion of men with a positive algorithm score who are
actual cases of osteoporosis and negative predictive value
was defined as the proportion of men with a negative
algorithm result who are actual noncases of osteoporosis.
The AUROC curve was used as a measure of the overall
ability of each strategy to discriminate between men with and
without osteoporosis. Statistical analysis was performed
using SPSS 14.0 for Windows.
Results
Our study population included 202 men aged 50 to 88 years,
with a mean age of 64 years. Table 2 summarizes the
descriptive characteristics of the study cohort, including age
distribution, WHO criteria, and T-score. The age distribution
deserves attention as it includes a large number of
participants with less than 70 years (75.7%), i.e., belonging
to the group where a decision-aid tool is potentially more
influential.
Table 3 summarizes the descriptive characteristics of the
study cohort stratified on the basis of the three WHO
diagnostic categories.
The overall percentage of osteoporosis at lumbar spine,
femoral neck, or total hip was 16.8% (n=34). The
percentage of T-score≤−2.5 at each measurement site was
14.9% at lumbar spine (n=30), 5% at femoral neck (n=10),
and 1% at total hip (n=2). The percentage of men with
osteoporosis increased with age from 14.4% among men
aged ≥50 and <70 years (22/153) to 24.5% among men
aged ≥70 years (12/49). The WHO diagnostic categories
were associated with significant differences regarding
weight, body mass index (BMI), and all the risk assessment
tools under scrutiny (p<0.001), but not with age and height.
Because both the OSTA and OST included age as part of
the decision algorithm, we further investigated the relationship
Table 1 Three simple decision rules for bone mineral density testing
among postmenopausal women
Body weight criterion, test if
Weight<70 kg
Osteoporosis self-assessment tool for Asians, test if score<2
0.2×body weight in kilograms (truncate to yield an integer)−0.2×
age in years (truncate to yield an integer)
Osteoporosis self-assessment tool, test if score<2
0.2×(body weight in kilograms−age in years), truncate to yield an
integer
Table 2 Summary of descriptive characteristics of the study cohort
(n=202)
Age (years, mean ± SD) 63.77±8.22
Age group—n (%)
Age ≥50 and <70 years 153 (75.7)
Age ≥70 years 49 (24.3)
Height (cm, mean ± SD) 167.84±6.78
Weight (kg, mean ± SD) 76.23±10.77
Body mass index (kg/m2, mean ± SD) 27.05±3.42








OSTA score (mean ± SD) 2.52±2.87
OST score (mean ± SD) 2.18±2.59
a The lowest BMD T-score at the lumbar spine, femoral neck, or total
hip was considered
Osteoporos Int
between age and T-scores. We found a significant correlation
between age and femoral neck (rp=−0.26; p<0.001) and
total hip (rp=−0.19; p=0.008) T-scores but not between
age and lumbar spine T-score (rp=0.06; p=0.397). These
results likely reflect the fact that the spine BMD is often
increased by degenerative changes in the unselected
elderly population.
Table 4 shows the sensitivity, specificity, predictive
values, and AUROC curve of each decision rule for selecting
men with osteoporosis in the study cohort. Maximum
sensitivity (85.3% for OST, 76.5% for OSTA, and 82.4%
for BWC) was achieved with the highest cutoffs (OST/
OSTA<4 and BWC<80 kg), but at the cost of very low
specificities (32.7% for the OST, 42.9% for the OSTA, and
35.7% for the BWC), resulting in a larger number of
unnecessary DXA scans.
Best AUROC curves were for OST<3 (AUROC=0.632),
OSTA<3 (AUROC=0.659), and BWC<75 kg (AUROC=
0.674). Sensitivities at these cutoffs were 76.5% for the OST,
73.5% for the OSTA, and 73.5% for the BWC. Negative
predictive value, an important characteristic for the purpose
of this work, was also quite high at these cutoffs—91.3% for
OST, 91.6% for OSTA, and 92% for BWC.
Comparison was also made with the age criterion and
several age cutoffs were tested (≥60, 65, 70, 75, and 80 years
old). AUROC curves had bad performances and the 95%
confidence intervals (CIs) included 0.5 for all of them,
suggesting that they do not have enough discriminative
power to select men for BMD.
Discussion
There are three recommended steps in developing and testing
tools to aid clinical decision making: development, validation
in several cohorts, and impact assessment. Information on
Normal (n=65) Osteopenia (n=103) Osteoporosis (n=34) p
Age (years, mean ± SD) 62.84±7.16 63.80±8.36 65.46±9.52 0.322
Age group—n (%) 0.229
Age ≥50 and <70 years
(n=153)
52 (34.0) 79 (51.6) 22 (14.4)
Age ≥70 years (n=49) 13 (26.5) 24 (49.0) 12 (24.5)
Height (cm, mean ± SD) 169.29±6.49 167.45±6.72 166.26±7.19 0.075
Weight (kg, mean ± SD) 81.2±9.24 74.88±10.78 70.84±9.89 <0.001
BMI (kg/m2, mean ± SD) 28.34±2.90 26.68±3.44 25.66±3.56 <0.001
OSTA score (mean ± SD) 3.75±2.62 2.25±2.73 1.00±2.90 <0.001
OST score (mean ± SD) 3.25±2.37 1.92±2.51 0.91±2.54 <0.001
Table 3 Summary of descrip-
tive characteristics of the study
cohort according to the three
WHO diagnostic categories
(n=202)
The lowest BMD T-score at the
lumbar spine, femoral neck, or
total hip was considered
% of men selected SE, % SP, % PPV, % NPV, % AUROC (95% CI)
OST<1 30.7 47.1 72.6 25.8 87.1 0.598 (0.490–0.707)
OST<2 40.6 61.8 63.7 25.6 89.2 0.627 (0.524–0.731)
OST<3 54.5 76.5 50.0 23.6 91.3 0.632 (0.535–0.730)
OST<4 70.3 85.3 32.7 20.4 91.7 0.590 (0.492–0.688)
OSTA<1 21.3 38.2 82.1 30.2 86.8 0.602 (0.491–0.713)
OSTA<2 36.1 55.9 67.9 26.0 88.4 0.619 (0.513–0.724)
OSTA<3 47.0 73.5 58.3 26.3 91.6 0.659 (0.562–0.757)
OSTA<4 60.4 76.5 42.9 21.3 90.0 0.597 (0.497–0.697)
BWC<65 13.4 26.5 89.3 33.3 85.7 0.579 (0.467–0.691)
BWC<70 26.7 47.1 77.4 29.6 87.8 0.622 (0.514–0.731)
BWC<75 44.6 73.5 61.3 27.8 92.0 0.674 (0.577–0.771)
BWC<80 67.3 82.4 35.7 20.6 90.9 0.590 (0.492–0.689)
Age≥60 years 61.9 61.8 38.1 16.8 83.1 0.499 (0.393–0.606)
Age≥65 years 40.1 52.9 62.5 22.2 86.8 0.577 (0.471–0.684)
Age≥70 years 24.3 35.3 78.0 24.5 85.6 0.566 (0.457–0.676)
Age≥75 years 9.9 26.5 93.5 45.0 86.3 0.600 (0.486–0.713)
Age≥80 years 3.5 5.9 97.0 28.6 83.6 0.515 (0.406–0.623)
Table 4 Percentage of men
selected for DXA, SE, SP, PPV,
NPV, and AUROC curve of
each algorithm and for different
cutoffs, for correctly selecting
men with osteoporosis in the
study cohort (n=202)
BMD T-score≤−2.5 by lowest
value at the lumbar spine,
femoral neck, or total hip was
considered. Note: previously
validated cutoff values in post-
menopausal women—OST<2,
OSTA<2, and BWC<70 kg.
Comparison is also made with
the age criterion
SE sensitivity, SP specificity,
PPV positive predictive value,
NPV negative predictive value
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their utility in different populations is especially important in
order to establish the generalizability of these approaches and
to assure their validity in clinical practice as applied in
different clinical and epidemiological settings [21].
We analyzed the value of three simple decision algorithms
for selecting men for BMD in 202 Portuguese men aged 50
or more; mean age was 64 years and the prevalence of
osteoporosis was quite high in our population (16.8%),
highlighting the need for reliable screening tools for the
identification of men at risk for osteoporosis.
Compared to the majority of previous reports, this study
had the virtue of not being retrospective. It was a cross-
sectional study, performed in a nonclinical setting and in
a random population. Such results are more probably
generalizable than if the sample had been submitted to
imprecise preselection. Because the study sample was
randomly selected with no clinical exclusion criteria, we
cannot be sure that all osteoporotic patients had primary
osteoporosis; however, the prevalence of known secondary
causes of osteoporosis in our sample was very small, and this
aspect probably has very little effect on the value of our study.
Our population had a wide representation in terms of age,
height, weight, and BMD status (Table 2).
An important point of this study is the high proportion of
men aged <70 years (75.7%). Indeed, this is the group where
decision-aid tools are especially needed. In fact, several
authorities (including Portuguese) recommend that BMD
testing should be performed in all men aged more than
70 years regardless of additional risk factors [7, 8]. Several
age criterions were tested in our study and all of them
showed low discriminative power to select men for BMD.
Among the 34 men who had osteoporosis, only 12 (35.3%)
were aged 70 or more. The majority of osteoporosis cases
would be missed if this cutoff alone was used as a criterion
for selecting men for BMD.
The representativeness of our sample is further supported
by the association between WHO status, weight, and BMI
(Table 3) and by the correlation between femoral neck and
total hip T-scores and age. The relationship between WHO
status and the algorithms tested here is also clear.
Ideally, one screening test should be 100% sensitive and
100% specific. However, in practice, this does not occur:
Sensitivity and specificity are usually inversely related. A
test with good sensitivity is favored when a false-negative
result is more prejudicial for the patient than a false-positive
one (curable disease, early diagnosis associated with better
prognosis) or when the disease is uncommon. A test with a
good specificity is favored when a false-positive result is
more prejudicial for the patient than a false-negative one
(aggressive treatment, incurable disease, etc.).
Because there is no risk of harm to the patient from
unnecessary treatment or invasive diagnostic testing in case
of a false-positive result from the OST, OSTA, or BWC and
also because treatment for low BMD would only be initiated
upon confirmation by DXA, a safe and noninvasive
diagnostic procedure, more importance has to be given to
sensitivity rather than specificity. However, specificity must
be contained at reasonable levels in order to reduce
unnecessary testing and costs for the community and the
patient.
Simplicity is also of crucial importance to foster the
implementation of any screening tool and its impact in
practice. In this study involving white men aged 50 years or
more, using a cutoff of OST/OSTA<3 or BWC<75 kg, most
men with osteoporosis were successfully identified, with a
sensitivity of 76.5% for the OST, 73.5% for the OSTA, and
73.5% for the BWC. At these cutoffs, specificity was 50.0%
for the OSTA, 58.3% for the OST, and 61.3% for the BWC.
In other words, the OST and OSTA, based only on age and
weight, and BWC, based on weight alone, permit identifying
men at low risk of osteoporosis who would not need DXA
testing (respectively, 91.3%, 91.6%, and 92% of patients
classified as low risk with OST, OSTA, and BWC do not
have osteoporosis).
The use of a cutoff of OST/OSTA<2 or BWC<70 kg
would represent unacceptable losses in terms of sensitivity
(61.8% for the OST, 55.9% for the OSTA, and 47.1% for the
BWC) while the use of a cutoff of OST/OSTA<4 or BWC<
80 kg would represent unacceptable losses in terms of
specificity (32.7% for the OST, 42.9% for the OSTA, and
35.7% for the BWC), without relevant gains in terms of
sensitivity or NPV (for the OSTA and BWC, it would even
represent a loss in terms of NPV).
The above considerations have their reflection in the
AUROC curves (a measure of test accuracy), the cutoff
of OST/OSTA<3 and BWC<75 kg yielding the best
discriminatory performances—0.632 (95% CI, 0.535–
0.730) for the OST, 0.659 (95% CI, 0.562–0.757) for the
OSTA, and 0.674 (95% CI, 0.577–0.771) for the BWC.
Hochberg et al. [33] applied the OST index to two large
groups of men in Rotterdam and Baltimore. They found that
the OST predicted osteoporosis as measured by DXA, using
cutoffs similar to postmenopausal women (OST<2) and
reported a sensitivity and specificity of 79% and 51%,
respectively, for the Rotterdam study and 88% and 32% for
the Baltimore cohort. Adler et al. [34] used a multi-ethnic
sample of men extracted from pulmonary and rheumatology
clinics at an American veteran’s hospital and using a cutoff
of OST<3, obtained a sensitivity of 93%, and a specificity of
66%. Kung et al. [35], in a large sample of Chinese men,
validated the OST using a different cutoff (OST<0), with a
sensitivity of 81% and specificity of 66%. Ghazi et al. [36],
in a cohort of Moroccan men seen at an outpatient
rheumatology center and using a score of OST<2, found
that sensitivity was 64.0% and specificity was 60.3% for OP
at any given BMD measurement site. Sinnott et al. [37]
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conducted a study in a cohort of African American males
aged 35 or older, and using a cutoff value of OST<4, they
predicted low bone mass (defined as a T-score of −2 or less
at the total hip, femoral neck, or trochanter) with a sensitivity
of 83% and a specificity of 57%; using the cutoff value of
BWC<85 kg, they predicted low bone mass with a
sensitivity of 74% and a specificity of 50%. Skedros et al.
[38] found OST to be a useful osteoporosis screening tool in
a population of 158 nonhospitalized white men (mean age
67.5 years), reporting a sensitivity of 85% and a specificity
of 64% for an OST score<2. On the other hand, in a study
by Perez-Castrillon et al. [39], an OST cutoff of 2 was not
useful (sensitivity of 39%, specificity of 86%, and a
nonsignificant AUROC curve) in a population of 67 Spanish
men referred due to lumbar pain or suspected osteoporosis
(mean age 51 years). In the largest-scale evaluation of
osteoporosis screening tools (4,658 US Caucasian men and
1,914 Hong Kong Chinese men), published by Lynn et al.
[40], OST was useful in both populations, with a sensitivity
of 87.6% and a specificity of 36.1% for Caucasians and a
sensitivity of 91.4% and a specificity of 36.4 for Chinese,
when using a cutoff≤2 for Caucasians and a cutoff≤−1 for
Chinese.
Differences between studies highlight the importance of
assessing osteoporosis screening tools in different populations
and the need to define appropriate cutoffs for each population.
These reported differences may be explained by selection of
the population, demographic differences (namely age),
and ethnical and racial differences regarding body size,
composition, and BMD measurements. In our population,
the prevalence of osteoporosis in the femoral neck and
hip is quite low in comparison to the spine. This
probably reflects the relative youth of the men with
75.7% being younger than 70 as cortical bone loss tends
to occur later. The very low prevalence of osteoporosis
in femoral neck and hip may contribute to the finding
that body weight was a better predictor of bone density
than indices based on weight plus age.
Our results must be interpreted in the light of several
limitations: First, we did not test all decision algorithms that
have been published, rather excluding more complex
formulas. Self-selection of volunteers biased our population
sample toward higher levels of education and income (data
not shown). However, the impact of such deviations on the
evaluation of the performance of theses indices is probably
minor, as they are designed for application in practice
without consideration of other factors.
The practical application of these decision rules and risk
indices in facilitating clinical decisions and promoting
rational use of resources should be explored further,
including all potential benefits as well as harms, such as
those derived of labeling men at high risk for osteoporosis
[43]. The use of such algorithms should not preclude due to
consideration of other less common but important risk
factors. Men with a prior fragility fracture are at high risk
for osteoporosis and recurrent fracture and should be
referred for BMD testing to facilitate treatment decisions,
irrespective of other considerations [44, 45]. Similarly, men
with major risk factors for secondary osteoporosis should
discuss bone health and BMD testing independent of these
decision rules [46].
A larger population-based study would be valuable to
assure the scientific reliability of our findings and a direct
comparison with usual clinical practice would also be
valuable to determine if decision rule approaches provide
more optimal use of BMD testing [47].
In summary, we tested three risk tools at four different
cutoffs and found that results were better for the OST/
OSTA<3 and BWC<75 kg. Our results confirm the
validity of the OST, OSTA, and BWC to support physicians
and public health authorities to focus DXA testing on
individuals at increased risk of osteoporosis, thus increasing
its cost–effectiveness. With BWC being the simplest one
and having a statistical performance that is similar to the
others, our data strongly support the use of body weight as
the preferred method to select men for DXA scanning.
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